hit counter
Audentes Therapeutics, Inc. (BOLD) Stock News Sentiment & Price - Sentifly
BOLD - Sentifly



Your watchlist is empty. Go add some tickers to it!

Audentes Therapeutics, Inc. (BOLD)

BOLD Price and Sentiment
Positive, Negative
Loading chart...
BOLD Latest news
Rocket Pharmaceuticals Primed for Takeoff
2021-03-15 17:19

With all due respect to Elton John, the real Rocket Man is in Cranbury, New Jersey.

Investors Business Daily
Biotech Stocks Burn A Hole In Big Pharma's Pocket. Look For More In 2020
2019-12-13 12:19

Mergers and acquisitions have lit up biotech stocks, and the hot pace shows no sign of slowing in 2020. Gene therapy and oncology companies are targets.

The Motley Fool
Why Lands' End, Audentes Therapeutics, and ViewRay Jumped Today
2019-12-03 16:30

Find out how strategic moves helped a couple of these stocks.

The Motley Fool
Why Audentes Therapeutics Stock Is Skyrocketing Today
2019-12-03 14:55

Shares more than doubled after the gene therapy company announced that it has accepted a buyout offer. Here are the key details.

Investors Business Daily
This Gene Therapy Player Just Grabbed A $3 Billion Takeover Bid
2019-12-02 18:32

Japanese company Astellas Pharma is acquiring gene therapy biotech company Audentes Therapeutics for $3 billion, the companies said late Monday.

Seeking Alpha
Why Audentes' rAAV Gene Therapy Can Be A Game Changer
2019-08-09 10:02

4 newborns diagnosed with XLMTM no longer require a ventilator after being treated with BOLD's AT-132.

Seeking Alpha
Audentes Therapeutics, Inc. (BOLD) CEO Matt Patterson on Q2 2019 Results - Earnings Call Transcript
2019-08-06 22:27

Audentes Therapeutics, Inc. (BOLD) CEO Matt Patterson on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha
Audentes Therapeutics: Encouraging Progress In XLMTM, Pipeline Continues To Evolve
2019-05-28 09:24

Shares have risen by over 130% since my initial recommendation.

Zacks Investment Research
4 Gene Therapy Players Likely to Become Buyout Targets in 2019
2019-04-08 09:45

Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.

CNBC Television
Barron's Andrew Bary breaks down his top biotech bets
2019-03-03 19:00

CNBC's "Power Lunch" team discusses potential biotech buys focused on gene therapy with Andrew Bary, associate editor of Barron's.